Araris and Chugai enter ADC licensing agreement

Araris Biotech AG and Chugai Pharmaceutical Co., Ltd. announced the licensing of AraLinQ® technology for developing innovative ADC cancer therapies. By combining Araris’ conjugation platform with Chugai’s antibody engineering expertise, the collaboration aims to enhance treatment precision and tolerability. The partners view this milestone as a key step toward advancing the program into clinical development.